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INTRODUCTION
Coxiella burnetii is an obligate Gram-negative
intracellular bacterium that causes acute Q-fever
and chronic infections in humans [1]. Current
diagnostic methods for human Q-fever are based
on clinical presentation and supporting serologi-
cal evidence of response against Nine Mile refer-
ence whole cell antigens (phase I and phase II),
although these assays suffer from lack of unifor-
mity and speciﬁcity. An effective formalin-killed
whole cell vaccine (Q-Vax CSL Ltd Melbourne,
Vic., Australia), in use in Australia, is adminis-
tered to individuals who are skin test-negative
and serologically negative. Vaccination can result
in severe local or systemic adverse reactions [2],
especially when administered to previously in-
fected populations, and repeat vaccination can
induce severe persistent reactions. Consequently,
no vaccine is licensed in the USA. Although
cellular immunity, especially as mediated by
CD4+ T-cells, is known to be critical for protective
immunity[3], there is no satisfactory vaccine that
can be administered without prior screening for
immunity in populations at risk of potential
exposure to the agent. Thus, identiﬁcation of
immunodominant antigens of C. burnetii with
strong humoral and cellular immune responses
after infection and vaccination should aid in the
development of a safe and effective vaccine and
reliable serodiagnostic tests. To achieve these
goals, we developed a systematic platform to
comprehensively analyse the humoral and cellu-
lar immune responses to a wide array of C. bur-
netii antigens in the context of C. burnetii infection
or vaccination in animal models and humans.
MATERIALS AND METHODS
Human serum samples
Fifty-ﬁve immunoﬂuorescent antibody analysis (IFA)-positive
convalescent human sera were collected between 38 and
172 days after onset of clinical symptoms; they had phase II
IFA titres ranging from 1 : 160 to 1 : 5120. Five chronic Q-fever
sera were collected from endocarditis patients with persistent
C. burnetii infection. Thirty two IFA-negative human sera were
selected from our human serum library. Q-fever IFA responses
were determined with a Q-fever IFA IgG Kit (FOCUS Diag-
nostic, Cypress, CA, USA), according to the manufacturer’s
instructions.
ELISA
Ninety-six-well microplates (Fisher Scientiﬁc, Pittsburgh, PA,
USA) were coated with 100 lL of 2 lg ⁄mL antigen. Fifty
microlitres of diluted (1 : 50) human serum were tested by IgG
indirect ELISA. The cut-off was determined as the mean of
IFA-negative samples plus two standard deviations.
ELISPOT
C57BL ⁄ 6 mice and human leukocyte antigen (HLA) DR4
molecule transgenic mice (C57BL ⁄ 6-[KO]Abb-[Tg]DR-4) were
vaccinated with 10 lg ⁄mouse electron beam-inactivated
C. burnetii Nine Mile, phase I (RSA493). Antigen-speciﬁc inter-
feron (IFN)-c recall was measured by ELISPOT using puriﬁed
CD4+ T-cells isolated at 12 days post-vaccination. The fre-
quency of IFN-c-producing cells was counted, and a stimula-
tion index was calculated for each recombinant protein.
RESULTS
Six previously identiﬁed and ﬁve C. burnetii
protein array proteins selected because of IgG
responses with convalescent human sera were
expressed as His-tag fusion proteins in Escherichia
coli and puriﬁed by chromatography. Humoral
and cellular immune responses to puriﬁed re-
combinant proteins were tested by ELISA and
Corresponding author and reprint requests: J. E. Samuel,
Department of Microbial and Molecular Pathogenesis, Texas
A&M Health Science Center, 407 Reynolds Bldg, College
Station, TX 77843-1114, USA
E-mail: jsamuel@medicinetamhsc.edu.
No conﬂicts of interest declared.
 2009 The Authors
Journal Compilation  2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15 (Suppl. 2), 156–157
ELISPOT, respectively. The solubilized fraction of
mechanically lysed whole cells of Nine Mile
phase I was used as a positive control. Most
puriﬁed recombinant proteins reacted strongly
with a subset of convalescent human sera, and all
recombinant proteins were able to differentiate a
majority of IFA-positive sera from IFA-negative
sera. No individual recombinant protein could
detect all IFA-positive samples. The sensitivity
and speciﬁcity for each recombinant protein were
25–52% and 78–100%, respectively (Table 1). All
recombinant proteins reacted strongly with sera
from endocarditis patients and reacted weakly
with sera from vaccinated individuals. Cellular
immune responses to recombinant proteins were
evaluated by IFN-c ⁄CD4+ T-cell recall responses
in vaccinated C57BL ⁄ 6 and HLA-DR4 transgenic
mice. Distinct antigen-speciﬁc CD4+ T-cells were
generated after vaccination in different mice.
Seven and eight tested recombinant proteins
induced antigen-speciﬁc IFN-c ⁄CD4+ T-cell recall
responses in vaccinated C57BL ⁄ 6 and HLA-DR4
transgenic mice, respectively (Table 1).
CONCLUSIONS
Humoral and cellular immune responses to 11
recombinant proteins were evaluated in this
study. Although none of the individual antigens
provided complete detection of all positive serum
samples, one or more antigens reacted with each
serum, indicating that combinations of two or
more antigens could increase sensitivity. In accor-
dance with previous studies showing that murine
and human MHCs recognize different epitopes
[4], we found that antigen-speciﬁc CD4+ T-cells
were generated differently in HLA-DR4 trans-
genic mice and wild-type mice; this conﬁrms that
the HLA transgenic mouse is a more relevant
model for screening human T-cell antigens. Most
proteins with strong antibody responses also
strongly induced IFN-c ⁄ recall responses in puri-
ﬁed CD4+ T-cells of vaccinated mice, which
means that immunoreactive antigen screening
based on serology testing, such as protein micro-
array, can aid in the discovery of T-cell antigens.
We have developed a sensitive, high-throughput
approach for screening immunoreactive C. bur-
netii antigens for strong humoral and cellular
immune responses. This platform will be used for
the rational design of effective subunit vaccines
and serodiagnostic tools.
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Table 1. ELISA sensitivity, speciﬁcity and interferon-c recall responses in C57BL ⁄ 6 and HLA-DR4 transgenic mice using
Coxiella burnetii recombinant proteins
ID
Molecular









NMI BBS 87.5 85  
CBU0383 24 DNA-3-methyladenine glycosidase I 87.5 31.6  
CBU0612 19 Outer membrane protein OmpH, putative 81.2 51.6 
CBU0718 10.4 Hypothetical membrane-associated protein 78.1 45 
CBU0781 38.5 Ankyrin repeat domain protein 81.3 40  
CBU0891 34.4 Hypothetical exported membrane protein 80.6 41.6 
CBU0311 29 Major outer membrane protein porin (P1) 78.1 43.3  
CBU0395 25 Lipoprotein, putative 90 28.3 
CBU0952 28 Outer membrane protein AdaA 100 25
CBU1221 22 Lipoprotein, putative 81.2 48.3 
CBU1716 35 Glycine cleavage system T-protein 90 46.6  
CBU1910 27 Outer membrane protein (Com1) 90 50  
HLA, human leukocyte antigen; MHC, major histocompatibility complex.
Sensitivity was calculated using number of ELISA-positive samples from the IFA-positive pool divided by the total number of IFA-positive samples. Speciﬁcity was calculated
using the number of ELISA-negative samples from the IFA-negative pool divided by the total number of IFA-negative samples. A tick mark () indicates a stimulation index
higher than three (stimulation index was calculated using number of spot-forming cells in vaccinated mice divided by number of spot-forming cells in naı¨ve mice). NMI BBS
was prepared from a solubilized fraction of mechanically lysed Nine Mile phase I (RSA493).
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